Evaluation of the Roche COBAS® TaqMan® HIV-1 test for quantifying HIV-1 RNA in infected cells and lymphoid tissue

Journal of Virological Methods

Volumn 174, Issue 1-2, 2011, Pages 69-76

  Gil, Cristina ^a   Garcia, M Teresa ^a   Garcia, Felipe ^a   Miró, José M ^a   Agüero, Fernando ^a   Alós, Lucía ^a   Zamora, Laura ^a   Capón, Alicia ^a   Costa, Josep ^a   Pumarola, Tomás ^a   Gatell, José M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

COBAS taqMan HIV 1; HIV 1 RNA quantitation; Lymphoid tissue

Indexed keywords

ANTIRETROVIRUS AGENT; DEOXYRIBONUCLEASE I; DNA; VIRUS RNA;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DILUTION; FALSE POSITIVE RESULT; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; LIMIT OF DETECTION; LYMPHOID TISSUE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY; RNA ANALYSIS; RNA EXTRACTION; SENSITIVITY AND SPECIFICITY; T LYMPHOCYTE; TONSIL; VIRUS LOAD;

CELLS, CULTURED; HIV-1; HUMANS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; PALATINE TONSIL; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; T-LYMPHOCYTES; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79955777644     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2011.03.026     Document Type: Article

References (20)

1. Chun T.W., Fauci A.S. Latent reservoirs of HIV: obstacles to the eradication of virus. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:10958-10961.
2. Chun T.W., Justement J.S., Lempicki R.A., Yang J., Dennis G., Hallahan C.W., Sanford C., Pandya P., Liu S., McLaughlin M., Ehler L.A., Moir S., Fauci A.S. Gene expression and viral production in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:1908-1913.
3. Dyrhol-Riise A.M., Voltersvik P., Berg O.G., Olofsson J., Kleivbo S., Asjö B. Residual human immunodeficiency virus type 1 infection in lymphoid tissue during highly active antiretroviral therapy: quantitation and virus characterization. AIDS Res. Hum. Retroviruses 2001, 17:577-586.
4. Fischer M., Huber W., Kallivroussis A., Ott P., Opravil M., Lüthy R., Weber R., Cone R.W. Highly sensitive methods for quantitation of human immunodeficiency virus type 1 RNA from plasma, cells, and tissues. J. Clin. Microbiol. 1999, 37:1260-1264.
5. Folks T.M., Powell D., Lightfoote M., Koenig S., Fauci A.S., Benn S., Rabson A., Daugherty D., Gendelman H.E., Hoggan M.D., Venkatesan S., Martin M.A. Biological and biochemical characterization of a cloned Leu-3-cell surviving infection with the acquired immune deficiency syndrome retrovirus. J. Exp. Med. 1986, 164:280-290.
6. Goujard C., Bonarek M., Meyer L., Bonnet F., Chaix M.L., Deveau C., Sinet M., Galimand J., Delfraissy J.F., Venet A., Rouzioux C., Morlat P. CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin. Infect. Dis. 2006, 42:709-715. Agence Nationale de Recherche sur le Sida PRIMO Study Group.
7. Guadalupe M., Sankaran S., George M.D., Reay E., Verhoeven D., Shacklett B.L., Flamm J., Wegelin J., Prindiville T., Dandekar S. Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection. J. Virol. 2006, 80:8236-8247.
8. Han Y., Wind-Rotolo M., Yang H.C., Siliciano J.D., Siliciano R.F. Experimental approaches to the study of HIV-1 latency. Nat. Rev. Microbiol. 2007, 5:95-106.
9. Kuster H., Opravil M., Ott P., Schlaepfer E., Fischer M., Günthard H.F., Lüthy R., Weber R., Cone R.W. Treatment-induced decline of human immunodeficiency virus-1 p24 and HIV-1 RNA in lymphoid tissue of patients with early human immunodeficiency virus-1 infection. Am. J. Pathol. 2000, 156:1973-1986.
10. Martínez E., Arnedo M., Giner V., Gil C., Caballero M., Alós L., García F., Holtzer C., Mallolas J., Miró J.M., Pumarola T., Gatell J.M. Lymphoid tissue viral burden and duration of viral suppression in plasma. AIDS 2001, 15:1477-1482.
11. Navarrete P., Morente V., García F., Alós L., Arnedo M., Plana M., Gil C., Caballero M., Miró J.M., Martínez E., Fumero E., Castro P., Blanco J.L., Mallolas J., Blanch J.L., Cruceta A., Mestre G., Pumarola T., Gallart T., Gatell J.M. Predictors of tonsillar tissue HIV-1 viral burden at baseline and after 1 year of antiretroviral therapy. Antivir. Ther. 2003, 8:635-637.
12. Nijhuis M., Boucher C.A., Schuurman R. Sensitive procedure for the amplification of HIV-1 RNA using a combined reverse-transcription and amplification reaction. Biotechniques 1995, 19:178-180.
13. Nijhuis M., Boucher C.A., Schipper P., Leitner T., Schuurman R., Albert J. Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:14441-14446.
14. Pasternak A.O., Adema K.W., Bakker M., Jurriaans S., Berkhout B., Cornelissen M., Lukashov V.V. Highly sensitive methods based on seminested real-time reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 unspliced and multiply spliced RNA and proviral DNA. J. Clin. Microbiol. 2008, 46:2206-2211.
15. Richman D.D., Margolis D.M., Delaney M., Greene W.C., Hazuda D., Pomerantz R.J. The challenge of finding a cure for HIV infection. Science 2009, 323:1304-1307.
16. Scott L.E., Noble L.D., Moloi J., Erasmus L., Venter W.D., Stevens W. Evaluation of the Abbott m2000 RealTime human immunodeficiency virus type 1 (HIV-1) assay for HIV load monitoring in South Africa compared to the Roche Cobas AmpliPrep-Cobas Amplicor, Roche Cobas AmpliPrep-Cobas TaqMan HIV-1, and BioMerieux NucliSENS EasyQ HIV-1 assays. J. Clin. Microbiol. 2009, 47:2209-2217.
17. Sizmann D., Glaubitz J., Simon C.O., Goedel S., Buergisser P., Drogan D., Hesse M., Kröh M., Simmler P., Dewald M., Gilsdorf M., Fuerst M., Ineichen R., Kirn A., Pasche P., Wang Z., Weisshaar S., Young K., Haberhausen G., Babiel R. Improved HIV-1 RNA quantitation by COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, v2.0 using a novel dual-target approach. J. Clin. Virol. 2010, 49:41-46.
18. Tierney C., Lathey J.L., Christopherson C., Bettendorf D.M., D'Aquila R.T., Hammer S.M., Katzenstein D.A. Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy. J. Infect. Dis. 2003, 187:144-148.
19. Troppan K.T., Stelzl E., Violan D., Winkler M., Kessler H.H. Evaluation of the new VERSANT HIV-1 RNA 1.0 Assay (kPCR) for quantitative detection of human immunodeficiency virus type 1 RNA. J. Clin. Virol. 2009, 46:69-74.
20. Zhang J., Crumpacker C.S. Human immunodeficiency virus type 1 RNA in peripheral blood mononuclear cells of patients receiving prolonged highly active antiretroviral therapy. J. Infect. Dis. 2001, 184:1341-1344.